158 filings
Page 4 of 8
8-K
glcf6x7e7lyj0lxxl18
17 Feb 21
Invitae Reports $279.6 Million in Annual Revenue Driven by 659,000 in Billable Volume in 2020
4:09pm
8-K
8ue0zwnvnei n1o
3 Feb 21
Other Events
5:25pm
8-K
3836k51
26 Jan 21
Invitae Announces Pricing of Public Offering of Common Stock
4:12pm
8-K
jtl6ymv7pp6i
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm
8-K
y885ua49
12 Jan 21
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume
6:06am
8-K/A
xakg xx0bt1qax289dm7
23 Nov 20
Consolidated Financial Statements
12:00am
8-K
2yy1fzwunx7 gt3b
23 Nov 20
Other Events
12:00am
8-K
jv9x22
9 Nov 20
Other Events
4:02pm
8-K
qco ietbd3s6xb5ye52
5 Nov 20
Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020
4:24pm
8-K/A
yuvc zayh3x
5 Oct 20
Submission of Matters to a Vote of Security Holders
4:21pm
8-K
wxko0ypxfah9tf
5 Oct 20
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
4:17pm
8-K
mqllwe26msfz4balgz9y
1 Oct 20
Submission of Matters to a Vote of Security Holders
4:09pm
8-K
l8lcgoftze 24a8
11 Sep 20
Departure of Directors or Certain Officers
4:17pm
8-K
q16qv7f8mnkphhv24j
4 Aug 20
Invitae Reports $46.2 Million in Revenue Driven by More Than 120,000 Samples Accessioned in the Second Quarter of 2020
4:13pm
8-K
n07xb
26 Jun 20
Departure of Directors or Certain Officers
4:06pm
8-K
h3fjihc5y ccsf
24 Jun 20
Entry into a Material Definitive Agreement
5:08pm
8-K
vprtc
22 Jun 20
Invitae and ArcherDX to create a global leader in comprehensive cancer genetics and precision oncology
4:55pm
8-K
7jb x8bead
18 Jun 20
Departure of Directors or Certain Officers
4:02pm
8-K
45v9erxz
12 Jun 20
Submission of Matters to a Vote of Security Holders
4:37pm
8-K
j2owageztfpv8d44d6k
22 May 20
Departure of Directors or Certain Officers
5:04pm